

# Challenging Case from Japan

Norio Tada  
Sendai Kousei Hospital

APVALE 2017



**Speaker's name: Norio Tada**

**I have the following potential conflicts of interest to report:**

TF proctor: Edwards Lifesciences

# 62 yrs old male

- 176cm 52kg
- CHF (NYHA 4)
- Severe ASR
- Bicuspid aortic valve
- Coarctation of aorta (ABI=0.7)
- LV dysfunction (EF=16%, LVDD=80mm)

## 62 yrs old male

- He repeated CHF hospitalization since Q1 in 2016.
- Severe ASR due to bicuspid AV and Coarctation aorta was pointed at the time.
- Surgery under LVAD support was our heart team decision last summer, and transferred to a University hospital.
- However he denied surgery.
- He hospitalized again due to CHF in Jan 2017.
- He was NYHA 4 under DOB support.



PHILIPS

FR 47Hz  
17cm  
**2D**  
66%  
C 50  
P Low  
HGen

G  
P 1.7 R 3.4

TIS0.8 MI 1.4

S5-1/Adult

M3




JPEG  
116 bpm

PHILIPS

FR 10Hz  
17cm


**2D**  
66%  
C 50  
P Low  
HGen  
**CF**  
66%  
2.5MHz  
WF High  
Med

✓




JPEG  
112 bpm


EF= 16%  
LVDD=80 LVSD 74mm  
AoF 2.79 m/s  
PPG 31 mmHg  
MPG 17 mmHg  
AVA 0.89cm<sup>2</sup>  
Severe AR



AOG: severe AR and very dilated LV



50344847: 13  
124.750mm  
0.0D  
(297.243)  
VOLUME\_CT



BYSTAGE 370/3.8ml(45)/3.0ml(23)/00:58.6  
Aquilion ONE  
LAO: 120.7

HALF  
30%  
62Y/M  
SU/FF/VFF  
volumeXact+/FC04/AIDR 3D/STD

120kV/ 89mA<sub>s</sub>  
0.28s/0.5mm  
HLF

50344847: 13  
124.750mm  
0.0D  
(297.243)  
VOLUME\_CT



BYSTAGE 370/3.8ml(45)/3.0ml(23)/00:58.6  
Aquilion ONE  
LAO: 60.1  
CRA: 50.1


HALF  
30%  
82Y/M  
SU/FF/VFF  
volumeXact+/FC04/AIDR 3D/STD  
仙台厚生病院

Bicuspid aortic valve  
type1 Fusion of RCC and LCC

Annulus area 651mm<sup>2</sup>  
SOV 47 x 48 x 50 mm

STJ diameter 41mm  
RCA height 23.6 mm  
LCA height 51.1 mm

# Coarctation of Aorta



STS predicted mortality for single AVR  
21.6%




# Problem list


- Instable hemodynamics
- Severe LV dysfunction
- Bicuspid AV
- Less calcified and large AV
- CoA


# Strategy

1. General anesthesia, TEE guide, without PCPS (ECMO)
2. CoA
  - Pre dilation 10mm
  - 32 mm ZENITH TX2 TAA Endovascular Graft (COOK)
  - Post dilation 16mm
3. TF-TAVI
  - SAPIEN 3 29mm, direct implantation, 1.4% oversize
  - +4ml filled in inflation device




# 32 mm ZENITH TX2 TAA Endovascular Graft (COOK)











LAO 6°  
CAU 33°  
SID 114 cm  
R3 8°  
C-L -13 mm  
I-L -3 mm  
O-L 80°  
✓ 36 s  
④ M 63.8 mm  
1641.64 cm/s  
27105 cm/s/s  
⑤ 09:25





# 5 months f/u

## LVDD 80 → 58mm



Pre

5 month

# Summary

- SAPIEN 3 delivery system was delivered through the stentgraft for CoA.
- SAPIEN 3 was effective for large, less calcified, bicuspid, and primary AR aortic valve.



# Coarctation of the Aorta: Stenting in Children and Adults

Alex B. Golden, \* MD, and William E. Hellenbrand, MD





Fig. 2. (a) The Palmaz XL 10-series stents are sturdy and expandable to full adult size, but the stents shorten considerably with full expansion. (b) The "sigma" hinge in the Genesis stents allows the stents to flex around curves and prevents significant shortening on expansion, but these stents cannot

be expanded beyond 18 mm. (c) The ev3 Intrastent Max LD is expandable to full size, is flexible and does not significantly shorten. (d) The C-P stents made by NuMed are made of platinum wire with rows of zigzags to allow full-size expansion with minimal shortening and good radial strength.

# Coarctation of the Aorta: Stenting in Children and Adults

Alex B. Golden, \* MD, and William E. Hellenbrand, MD



- Tagはむきだし、tx2は収納されている
- Tagは真ん中からひらく、tx2ははじからひらく
- Tagはスリップのリスク
- Tagのほうがtortuoustyにつよい。Txは段々
- 10-20% oversizing
- 左鎖骨下A、温存。形としてはイマイチではあるが、弓部をカバーしにいくのはやりすぎ。本来の目的と異なる。つぶすとそれなりに虚血が生じる。しびれ。若いということを考えると温存でよい。動脈瘤の場合はendoleakを考えて左鎖骨下カバーもありえるが、coarctationではendoleakは関係ない。
- 予後、再狭窄はまだわからない
- Ptaバルーン16mmのポストはどこまで広げるかはまだわからないが、とりあえず血行動態的な狭窄を解除し、ruptureしないことが第一目的。
- 再狭窄したら再度バルーンという手段もあり。

# Letters

## Transcatheter Aortic Valve Replacement to Treat Pure Aortic Regurgitation on Noncalcified Native Valves



CrossMark

Marina Urena, MD, PhD

\*Dominique Himbert, MD

Patrick Ohlmann, MD, PhD

Giuliana Capretti, MD

Coppelia Goublaire, MD


Michel Kindo, MD

Olivier Morel, MD

Walid Ghodbane, MD

Bernard Jung, MD, PhD

Alec Vahanian, MD



\*Overall a prosthesis/annulus oversizing of 15% to 25% is recommended. †Prosthesis size and extra volume may vary according to LVOT dimensions. ‡Suitability of TAVR depends on LVOT dimensions. AR = aortic regurgitation; CT = computed tomography; LVOT = left ventricular outflow tract; TAVR = transcatheter aortic valve replacement; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography.

